William G. Wierda, MD, PhD, on CLL/SLL: 3-Year Follow-up Data on Ibrutinib Plus Venetoclax

Posted: Monday, June 27, 2022

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the CAPTIVATE study, which showed that fixed-duration first-line treatment with ibrutinib plus venetoclax continues to provide deep, durable responses and clinically meaningful progression-free survival in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high-risk disease features. This regimen represents an all-oral, once-daily, chemotherapy-free treatment.